



HHS Public Access

Author manuscript

Clin Cancer Res. Author manuscript; available in PMC 2015 August 24.

Published in final edited form as:

Clin Cancer Res. 2013 December 1; 19(23): 6338–6343. doi:10.1158/1078-0432.CCR-13-0614.

New Strategies in Radiation Therapy: Exploiting the Full Potential of Protons

Radhe Mohan¹, Anita Mahajan², and Bruce D. Minsky²

¹Department of Medical Physics, Division of Radiation Oncology, University of Texas MD Anderson Cancer Center

²Department of Radiation Oncology, Division of Radiation Oncology, University of Texas MD Anderson Cancer Center

Abstract

Protons provide significant dosimetric advantages compared with photons due to their unique depth-dose distribution characteristics. However, they are more sensitive to the effects of intra- and inter-treatment fraction anatomic variations and uncertainties in treatment setup. Furthermore, in the current practice of proton therapy, the biological effectiveness of protons relative to photons is assumed to have a generic fixed value of 1.1. However, this is a simplification, and it is likely higher in different portions of the proton beam. Current clinical practice and trials have not fully exploited the unique physical and biological properties of protons. Intensity-modulated proton therapy, with its ability to manipulate energies (in addition to intensities), provides an entirely new dimension, which, with ongoing research, has considerable potential to increase the therapeutic ratio.

Background

Research and development in the last three decades has led to considerable improvement in our understanding of dose and dose-volume response to radiotherapy. Radiation, with and without cytotoxic and targeted chemotherapy, impacts a variety of molecular pathways in normal and tumor tissues (1). Moreover, increasingly powerful tools to target tumors more precisely with higher radiation doses while sparing normal tissues have been developed. These tools have included 3-dimensional conformal radiation therapy (3D-CRT) in the 1980's, intensity-modulated [photon] radiotherapy (IMRT) in the 1990s, and proton therapy in the last decade.

High energy photons are the most common radiation modality used for external beam radiation therapy. They have well described and understood physical characteristics and biological effectiveness. As shown in Figure 1 (green curve), high energy photons deliver a dose that increases at very shallow depths and then decreases exponentially as they pass

Address correspondence to: Bruce D. Minsky, Department of Radiation Oncology, UT MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 97, Houston, TX 77030.

Conflicts of Interest: RM holds a commercial research grant from Philips. AM holds a commercial research grant from Varian Medical Systems. BDM is the Co-chair of the NCI GI Steering Committee and ASTRO President elect.

through the body. This results in unwanted dose to normal tissues proximal and distal to the tumor.

In the modern practice of photon radiotherapy, intensities of small subdivisions of beams known as “beamlets” are optimally adjusted to balance the dose requirements of the tumor vs. normal tissues and the normal tissues among themselves. This mode of photon treatments is known as IMRT. However, even with such advancements, the physical characteristics of photons limit the ability to escalate dose since normal tissues in their path receive significant doses of radiation.

Protons provide dosimetric advantages compared with photons. This advantage stems from their unique depth-dose distribution characteristics. As protons enter the body and slow down on their way to the target, the dose deposited per unit path length increases, initially slowly and then progressively rapidly, until the energy of the protons is fully depleted and they come to a complete stop. This results in a dose deposition pattern with a peak (called the “Bragg peak”) and a sharp drop off in dose at the end of the range of the protons as depicted by the red curve in Figure 1. Protons, in contrast with photons, deliver no dose beyond the end of this range.

The biological effectiveness of protons relative to photons (i.e., “relative biological effectiveness” or RBE) has simplistically been assumed to have a generic fixed value of 1.1. RBE is defined as the ratio of the physical dose of a reference photon radiation to the physical dose of protons required to achieve the same biological effect. This assumption of generic RBE of 1.1 is based on an average of the results of numerous in-vitro and in-vivo experiments conducted under limited conditions and which have large error bars (2–4). Most commonly, these experiments were conducted at high doses per fraction (e.g., 6–8 Gy) and in the middle of the spread-out Bragg peak (SOBP, defined below and in Figure 1). The spectrum of proton energies in the middle of the SOBP is rather broad and depends on the SOBP width. There is a paucity of proton RBE data since designing experiments to determine proton RBE by proton energy are challenging and require large data sets. An accurate estimation of biological effectiveness of protons as a function of energy has not been reported. Furthermore, the RBE data have been acquired for only a limited number of cell lines, tissues and endpoints

There is increasing evidence that the RBE is a complex function of multiple variables including but not limited to dose deposited per unit path length (“linear energy transfer” or LET), dose per fraction, and tissue or cell type being treated (2–4). At a more fundamental level, the biological effects of protons differ significantly from those of photons due to the differences in the patterns of ionization and molecular excitations between the two modalities. Such events are densely concentrated along the path of protons and increase as the protons slow down in the medium, reaching a peak at the end of their range. In contrast, with photons these events are sparsely spread across the irradiated field. These differences lead to significant differences in the biological effects of the two modalities. Examples include greater complexity of DNA damage and greater production of free radicals with protons. Furthermore, the two modalities modulate different signaling pathways involved in apoptosis and there are data which suggest that protons have a greater proficiency in

inducing apoptotic cell death. They also regulate gene expression differently, leading to distinctly different transcriptome profiles. Girdhani, et al provide a comprehensive overview of current knowledge of biological effectiveness of protons relative to that of photons (5).

Most of the routine practice of proton therapy and the vast majority of proton-based clinical trials have used “passively scattered proton therapy” (PSPT). In this mode of proton therapy, in which a thin initial beam of protons is electromechanically modulated longitudinally and spread laterally to produce a “spread-out Bragg peak” (Figure 1, cyan curve); the advantage of the dose distribution characteristic of protons is exploited to some degree to reduce the low dose bath associated with IMRT in the normal tissues surrounding the target. However, as will be discussed in the New Horizons section, the clinical practice and trials to date have not fully exploited the unique physical as well as biological properties of proton therapy. This is, in part, due to the sensitivity of protons to changes in anatomy. These variations result from day-to-day differences in treatment position, intra-fractional motion (e.g., due to respiration) or inter-fractional changes such as tumor shrinkage or weight loss. The steep fall-off in dose at the end of the range of protons that makes them attractive for radiotherapy, unfortunately also makes them more sensitive to anatomic variations leading to uncertainty in the dose actually delivered. This uncertainty, combined with uncertainty in RBE, often inhibits the use of optimal treatment strategies such as reducing the treatment margins or utilizing beams aimed directly at certain normal critical anatomic structures. It should also be noted that, while protons reduce the low dose bath, the conformality of the high dose region immediately adjacent to the target is superior for IMRT compared to what is achievable in the current state of the art of protons.

Furthermore, potentially the most effective form of proton therapy, intensity-modulated proton therapy (IMPT), is still in its infancy. IMPT, with its ability to manipulate energies (in addition to intensities), has the power to shift the clinical paradigm to an entirely new dimension to maximize the therapeutic ratio. As will be explained later, in addition to exploiting physical properties of protons to a greater extent than PSPT, IMPT has the ability to take advantage of variable RBE to further increase the differential between tumor dose and normal tissue doses.

Clinical Trials

There is general acceptance of protons in the management of pediatric cancers since the reduction in normal tissue dose will result in a reduction of acute and late toxicities, including the risk of secondary malignancies, without compromising tumor control. Published data, however, are limited to small single institutional reports for a limited number of indications (6–15). Randomized trials in pediatric cancer comparing proton versus photon therapy are not feasible; therefore, a national registry has been created (16). Additional areas of interest are gastrointestinal and breast cancers, lymphoma, and recurrent cancers (15, 17–21). For example, for patients with breast cancer, proton therapy may provide a practical, safe and better alternative for management of deep internal mammary lymph nodes, or other anatomic situations where conventional radiation approaches are limited by normal adjacent structures (17–19). Proton therapy is also an attractive alternative for selected patients with recurrent disease in or near a previously irradiated site (22, 23).

Phase I and II clinical trials (non-randomized) are examining the role of proton radiation in adults. These include included skull base chordomas and chondrosarcomas (14, 24), ocular melanomas (25) prostate cancer (26–28), paranasal sinus tumors (29) nasopharyngeal carcinomas (12, 30), spine sarcomas (24, 31), non-small cell lung cancer (32–36), and hepatocellular carcinomas (37, 38). Overall, these trials have demonstrated two major advantages. First, dose escalation with protons is potentially achievable. For example, the treatment of the reduced dose bath allows for a higher prescription dose for protons and, therefore, would lead to superior local control versus photons (39, 40). Second, protons reduce the normal tissue integral radiation dose with the potential to significantly lower rates of normal tissue toxicity.

There have been four published randomized trials utilizing protons. Clinical sites include locally advanced prostate cancers (41, 42), chordomas and skull base chondrosarcomas (43) and choroidal melanoma (25). In these trials, protons were used as a boost and the randomization was between two proton doses. Currently, there are over 50 active phase II and III trials in the United States specifically evaluating proton therapy in a variety of clinical sites. Of these, phase II and III randomized trials comparing photons and protons are ongoing in oropharyngeal cancer, esophageal cancer, lung cancer, glioblastoma, and prostate cancer. The primary endpoints are toxicity, functional outcome, and quality of life. There are an additional 18 observational/registry studies that are actively collecting data (16).

New Horizons

IMPT is an innovative technology that is inherently more powerful than both PSPT and IMRT because of its ability to modulate energies as well as intensities. In contrast, IMRT modulates intensities only and PSPT modulates neither (44). IMPT offers the ability to exploit the physical as well as biological potential of proton radiotherapy to a considerably greater degree. However, IMPT is more sensitive to uncertainties than PSPT and even more so compared to IMRT (45). Considerable research and development is needed and is being undertaken to realize IMPT's full potential. Even in its current relatively immature form, it has been used in a few institutions to confirm feasibility and identify potential benefits over PSPT and highly conformal x-ray based technologies, such as IMRT and its variants (VMAT and tomotherapy) (46–49). Patients have been treated safely and effectively with IMPT for tumors of the prostate, head and neck, CNS, spine and lung.

IMPT utilizes thin scanning beamlets of protons to “paint radiation dose” onto the target volumes. The energy of the beamlets is varied to paint the target layer-by-layer. The intensities of beamlets comprising multiple scanning beams, aimed at the tumor from different directions, are determined using computer-aided mathematical optimization methods to balance the tumor dose versus the limits of normal tissue tolerances. Because of its ability to control proton energies, IMPT dose distributions are, in general, vastly superior not only to the corresponding photon-based techniques such as IMRT but also to PSPT. Figure 2 shows an example comparing IMPT with IMRT dose distributions.

IMPT aims to achieve a homogeneous dose to the tumor target. In order to optimally balance target and normal tissue doses, the optimization process would, in general, lead to

highly inhomogeneous target dose contributed by each of the individual beams. The inhomogeneous dose patterns from individual beams are presumed to be perfectly matched to produce a homogeneous target dose. However, because of uncertainties in dose distributions, mismatches can occur, and the actual target dose patterns delivered may be quite inhomogeneous.

Therefore, a multi-pronged approach is needed to maximize the potential of IMPT. In-room volumetric image guidance is essential to minimize the uncertainty in daily positioning, and respiratory gating or breath-hold delivery is critical to minimize the effect of respiratory motion of the anatomy on dose distributions. Repeat imaging (typically weekly) is necessary to examine the changing anatomy and its impact on dose distribution. If an anatomic change would result in inadequate treatment, a new treatment plan will be designed to adapt to the changed anatomy. To account for residual uncertainties, “robust optimization” methodology is used to make dose distributions more resilient (45, 50). Such methods have been employed in other fields such as statistics, operations research, finance and engineering in order to achieve robustness against uncertainties. The initial application of robust optimization to IMPT has been limited to uncertainties in patient positioning and in the range of protons. Additional research is needed to include uncertainties in inter- and intra-fractional anatomic variations. Although these measures would benefit both IMRT and PSPT, they are critical for IMPT (50–53).

While the robust optimization of IMPT dose distributions based solely on the physical properties of protons would lead to substantial gains, the incorporation of the variable nature of RBE will yield maximum dividends (54, 55). As seen in Figure 3, the RBE at the top of the Bragg peak may be as high as 1.5 instead of the assumed value of 1.1. Methods are being developed to selectively place the high RBE portions of the Bragg peak within the target volume and sufficiently away from critical normal tissues. This would lead to increased biologically effective dose within the target and reduced doses to normal tissues. In one such strategy, called “Distal Edge Avoidance”, the beamlets of a beam contributing the distal-most portion of the target would be omitted. Any low dose regions thus created would be compensated for by beamlets from other beam directions. An example of this is seen in Figure 3. However, as pointed out above, there are significant gaps in our knowledge of RBE data and, therefore, there a major effort needs to be mounted to conduct *in-vitro* and *in-vivo* experiments to acquire biological effects data and also to derive them from clinical response data.

Summary

In summary, the state of the art of radiotherapy has considerably and continually improved over the last three decades. The most recent development is proton therapy, which is still evolving. However; even in its current form, it has reduced dose to normal structures, helped reduce acute toxicities and has been proven to be safe and effective. Continued research and development and the use of IMPT provides the opportunity to exploit the full physical and biological potential of proton therapy and to demonstrate its superiority over the most advanced photon based techniques currently used.

Acknowledgments

Funding: Two of the authors (AM and RM) are supported partially by Award Number P01CA021239 entitled 'Optimizing Proton Therapy' from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute (NCI) or the National Institutes of Health.

References

1. Liauw SL, Connell PP, Weichselbaum RR. New paradigms and future challenges in radiation oncology: an update of biological targets and technology. *Sci Transl Med.* 2013; 5:173sr2. [PubMed: 23427246]
2. Paganetti H, Niemierko A, Ancukiewicz M, Gerweck LE, Goitein M, Loeffler JS, et al. Relative biological effectiveness (RBE) values for proton beam therapy. *Int J Rad Oncol Biol Phys.* 2002; 53:407–21.
3. Gerweck LE, Kozin SV. Relative biological effectiveness of proton beams in clinical therapy. *Radiother Oncol.* 1999; 50:135–42. [PubMed: 10368035]
4. Britten RA, Nazaryan V, Davis LK, Klein SB, Nichiporov D, Mendonca MS, et al. Variations in the RBE for cell killing along the depth-dose profile of a modulated proton therapy beam. *Radiation Research.* 2013; 179:21–8. [PubMed: 23148508]
5. Girdhani S, Sachs R, Hlatky L. Biological effects of proton radiation: what we know and don't know. *Radiation Research.* 2013; 179:257–72. [PubMed: 23373900]
6. Kuhlthau KA, Pulsifer MB, Yeap BY, Rivera Morales D, Delahaye J, Hill KS, et al. Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. *J Clin Oncol.* 2012; 30:2079–86. [PubMed: 22565004]
7. Amsbaugh MJ, Grosshans DR, McAleer MF, Zhu R, Wages C, Crawford CN, et al. Proton therapy for spinal ependymomas: planning, acute toxicities, and preliminary outcomes. *Int J Rad Oncol Biol Phys.* 2012; 83:1419–24.
8. Moeller BJ, Chintagumpala M, Philip JJ, Grosshans DR, McAleer MF, Woo SY, et al. Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy. *Radiat Oncol.* 2011; 6:58. [PubMed: 21635776]
9. Cotter SE, Herrup DA, Friedmann A, Macdonald SM, Pieretti RV, Robinson G, et al. Proton radiotherapy for pediatric bladder/prostate rhabdomyosarcoma: clinical outcomes and dosimetry compared to intensity-modulated radiation therapy. *Int J Rad Oncol Biol Phys.* 2011; 81:1367–73.
10. MacDonald SM, Yock TI. Proton beam therapy following resection for childhood ependymoma. *Childs Nerv Syst.* 2010; 26:285–91. [PubMed: 20024657]
11. Habrand JL, Schneider R, Alapetite C, Feuvret L, Petras S, Datchary J, et al. Proton therapy in pediatric skull base and cervical canal low-grade bone malignancies. *Int J Rad Oncol Biol Phys.* 2008; 71:672–5.
12. DeLaney TF. Clinical proton radiation therapy research at the Francis H. Burr Proton Therapy Center. *Technol Cancer Res Treat.* 2007; 6:61–6. [PubMed: 17668954]
13. Yock T, Schneider R, Friedmann A, Adams J, Fullerton B, Tarbell N. Proton radiotherapy for orbital rhabdomyosarcoma: clinical outcome and a dosimetric comparison with photons. *Int J Rad Oncol Biol Phys.* 2005; 63:1161–8.
14. Hug EB, Sweeney RA, Nurre PM, Holloway KC, Slater JD, Munzenrider JE. Proton radiotherapy in management of pediatric base of skull t. *Int J Rad Oncol Biol Phys.* 2002; 52:1017–24.
15. Li J, Dabaja B, Reed V, Allen PK, Cai H, Amin MV, et al. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. *Int J Rad Oncol Biol Phys.* 2011; 81:167–74.
16. NIH, NLM. National Library of Medicine (NLM) National Institutes of Health (NIH); 2013. ClinicalTrials.gov
17. Macdonald SM, Patel SA, Hickey S, Specht M, Isakoff SJ, Gadd M, et al. Proton therapy for breast cancer after mastectomy: early outcomes of a prospective clinical trial. *Int J Rad Oncol Biol Phys.* 2013; 86:484–90.

18. Wang X, Amos RA, Zhang X, Taddei PJ, Woodward WA, Hoffman KE, et al. External-beam accelerated partial breast irradiation using multiple proton beam configurations. *Int J Rad Oncol Biol Phys.* 2011; 80:1464–72.
19. Bush DA, Slater JD, Garberoglio C, Do S, Lum S, Slater JM. Partial breast irradiation delivered with proton beam: results of a phase II trial. *Clin Breast Cancer.* 2011; 11:241–5. [PubMed: 21729673]
20. Knausl B, Lutgendorf-Caucig C, Hopfgartner J, Dieckmann K, Kurch L, Pelz T, et al. Can treatment of pediatric Hodgkin's lymphoma be improved by PET imaging and proton therapy? *Strahlenther Onkol.* 2013; 189:54–61. [PubMed: 23161118]
21. Hoppe BS, Flampouri S, Lynch J, Slayton W, Zaiden R, Li Z, et al. Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy. *Oncology (Williston Park).* 2012; 26:456–9. 62–5. [PubMed: 22730602]
22. Stusckie M, Kaiser A, Abu-Jawad J, Pottgen C, Levegrun S, Farr J. Re-irradiation of recurrent head and neck carcinomas: comparison of robust intensity modulated proton therapy treatment plans with helical tomotherapy. *Radiat Oncol.* 2013; 8:93. [PubMed: 23601204]
23. Jensen AD, Nikoghosyan A, Ellerbrock M, Ecker S, Debus J, Munter MW. Re-irradiation with scanned charged particle beams in recurrent tumours of the head and neck: acute toxicity and feasibility. *Radiother Oncol.* 2011; 101:383–7. [PubMed: 21640421]
24. Noel G, Feuvret L, Calugaru V, Dhermain F, Mammari H, Haie-Meder C, et al. Chordomas of the base of the skull and upper cervical spine. One hundred patients irradiated by a 3D conformal technique combining photon and proton beams. *Acta Oncol.* 2005; 44:700–8. [PubMed: 16227160]
25. Gragoudas ES, Lane AM, Regan S, Li W, Judge HE, Munzenrider JE, et al. A randomized controlled trial of varying radiation doses in the treatment of choroidal melanoma. *Arch Ophthalmol.* 2000; 118:773–8. [PubMed: 10865313]
26. Nomiya T, Tsuji H, Toyama S, Maruyama K, Nemoto K, Tsujii H, et al. Management of high-risk prostate cancer: Radiation therapy and hormonal therapy. *Cancer Treat Rev.* 2013 Epub ahead of print.
27. Coen JJ, Zietman AL, Rossi CJ, Grocela JA, Efstathiou JA, Yan Y, et al. Comparison of high-dose proton radiotherapy and brachytherapy in localized prostate cancer: a case-matched analysis. *Int J Rad Oncol Biol Phys.* 2012; 82:e25–31.
28. Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, et al. Acute and late toxicity after dose escalation to 82 GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03–12. *Int J Rad Oncol Biol Phys.* 2011; 81:1005–9.
29. Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, McIntyre J, Adams J, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. *Cancer.* 2002; 94:2623–34. [PubMed: 12173330]
30. Brown AP, Urie MM, Chisin R, Suit HD. Proton therapy for carcinoma of the nasopharynx: a study in comparative treatment planning. *Int J Rad Oncol Biol Phys.* 1989; 16:1607–14.
31. DeLaney TF, Liebsch NJ, Pedlow FX, Adams J, Dean S, Yeap BY, et al. Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. *Int J Rad Oncol Biol Phys.* 2009; 74:732–9.
32. Bonnet RB, Bush D, Cheek GA, Slater JD, Panossian D, Franke C, et al. Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable non-small cell lung cancer. *Chest.* 2001; 120:1803–10. [PubMed: 11742905]
33. Bush DA, Slater JD, Shin BB, Cheek G, Miller DW, Slater JM. Hypofractionated proton beam radiotherapy for stage I lung cancer. *Chest.* 2004; 126:1198–203. [PubMed: 15486383]
34. Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, et al. Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. *Cancer.* 2011; 117:4707–13. [PubMed: 21437893]

35. Chang JY, Komaki R, Wen HY, De Gracia B, Bluett JB, McAleer MF, et al. Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. *Int J Rad Oncol Biol Phys*. 2011; 80:1350–7.
36. Sejal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. *Cancer*. 2011; 117:3004–13. [PubMed: 21264827]
37. Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. *Gastroenterology*. 2004; 127:S189–93. [PubMed: 15508084]
38. Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. *J Clin Oncol*. 2005; 23:1839–46. [PubMed: 15774777]
39. Park L, Delaney TF, Liebsch NJ, Hornicek FJ, Goldberg S, Mankin H, et al. Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor. *Int J Rad Oncol Biol Phys*. 2006; 65:1514–21.
40. Terahara A, Niemierko A, Goitein M, Finkelstein D, Hug E, Liebsch N, et al. Analysis of the relationship between tumor dose inhomogeneity and local control in patients with skull base chordoma. *Int J Rad Oncol Biol Phys*. 1999; 45:351–8.
41. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McManus PL, et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. *Int J Rad Oncol Biol Phys*. 1995; 32:3–12.
42. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. *JAMA*. 2005; 294:1233–9. [PubMed: 16160131]
43. Santoni R, Liebsch N, Finkelstein DM, Hug E, Hanssens P, Goitein M, et al. Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull. *Int J Rad Oncol Biol Phys*. 1998; 41:59–68.
44. Lomax AJ, Bohringer T, Bolsi A, Coray D, Emert F, Goitein G, et al. Treatment planning and verification of proton therapy using spot scanning: initial experiences. *Medical Physics*. 2004; 31:3150–7. [PubMed: 15587667]
45. Liu W, Zhang X, Li Y, Mohan R. Robust optimization of intensity modulated proton therapy. *Medical Physics*. 2012; 39:1079–91. [PubMed: 22320818]
46. Weber DC, Wang H, Cozzi L, Dipasquale G, Khan HG, Ratib O, et al. RapidArc, intensity modulated photon and proton techniques for recurrent prostate cancer in previously irradiated patients: a treatment planning comparison study. *Radiat Oncol*. 2009; 4:34. [PubMed: 19740429]
47. Weber DC, Rutz HP, Pedroni ES, Bolsi A, Timmermann B, Verwey J, et al. Results of spot-scanning proton radiation therapy for chordoma and chondrosarcoma of the skull base: the Paul Scherrer Institut experience. *Int J Rad Oncol Biol Phys*. 2005; 63:401–9.
48. Timmermann B, Schuck A, Niggli F, Weiss M, Lomax AJ, Pedroni E, et al. Spot-scanning proton therapy for malignant soft tissue tumors in childhood: First experiences at the Paul Scherrer Institute. *Int J Rad Oncol Biol Phys*. 2007; 67:497–504.
49. Baumert BG, Norton IA, Lomax AJ, Davis JB. Dose conformation of intensity-modulated stereotactic photon beams, proton beams, and intensity-modulated proton beams for intracranial lesions. *Int J Rad Oncol Biol Phys*. 2004; 60:1314–24.
50. Liu W, Frank SJ, Li X, Li Y, Zhu RX, Mohan R. PTV-based IMPT optimization incorporating planning risk volumes vs robust optimization. *Medical Physics*. 2013; 40:021709. [PubMed: 23387732]
51. Stuschke M, Kaiser A, Abu Jawad J, Pottgen C, Levegrun S, Farr J. Multi-scenario based robust intensity-modulated proton therapy (IMPT) plans can account for set-up errors more effectively in terms of normal tissue sparing than planning target volume (PTV) based intensity-modulated photon plans in the head and neck region. *Radiat Oncol*. 2013; 8:145. [PubMed: 23773560]

52. Liu W, Frank SJ, Li X, Li Y, Park PC, Dong L, et al. Effectiveness of robust optimization in intensity-modulated proton therapy planning for head and neck cancers. *Medical Physics*. 2013; 40:051711. [PubMed: 23635259]
53. Casiraghi M, Albertini F, Lomax AJ. Advantages and limitations of the 'worst case scenario' approach in IMPT treatment planning. *Phys Med Biol*. 2013; 58:1323–39. [PubMed: 23391569]
54. Wilkens JJ, Oelfke U. Optimization of radiobiological effects in intensity modulated proton therapy. *Medical Physics*. 2005; 32:455–65. [PubMed: 15789592]
55. Frese MC, Wilkens JJ, Huber PE, Jensen AD, Oelfke U, Taheri-Kadkhoda Z. Application of constant vs. variable relative biological effectiveness in treatment planning of intensity-modulated proton therapy. *Int J Rad Oncol Biol Phys*. 2011; 79:80–8.




Figure 1. The green curve shows the depth dose data of a typical 15 MV photon beam. The red curve shows the depth dose curve of a monoenergetic proton beam. The maximum dose point of this curve is termed the Bragg peak. Scanning thin monoenergetic proton beams are used for intensity-modulated proton therapy. The cyan curve is obtained by electromechanically spreading the monoenergetic proton beam laterally and longitudinally and is used in passively scattered proton therapy. The top flat portion of this curve is called the spread-out Bragg peak. The potential advantages of proton vs. photon dose distributions are clear.




Figure 2. Comparison of IMRT and IMPT dose distributions in a thorax treatment plan. The large “low dose bath” in IMRT (left panels) is considerably reduced in IMPT dose distributions (right panels). (Courtesy Joe Y. Chang, PTCOG 47 presentation)




Figure 3.

Optimization of IMPT taking advantage of the physical and biologic characteristics of protons. The panel on the left shows illustrative Bragg curves for variable RBE (orange) and fixed RBE of 1.1 (blue). It shows that, over and above the dose advantage, the use of variable RBE may lead to an additional 40% differential (more in some cases, less in others) between normal tissue and tumor dose. A goal of current research is to selectively place the high RBE portions of the Bragg curve (represented by small translucent red and blue circles, or “spots”, in the right panel) within the gross target volume (GTV). If there is a normal critical structure present adjacent to the distal edge of the target volume along the beam direction, the intensities of spots (blue translucent circles) at the distal edge are set to zero. The underdosing in the target volume thus created at the distal edge is compensated by beamlets of beams from other directions.